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Abstract
Drug-resistant tuberculosis (TB) patients have a greater risk of loss to follow-up (LTFU) than drug-sensitive TB patients, due to their longer treatment duration.
This study aimed to determine the influence of decentralization and patient type on LTFU among multidrug-resistant TB (MDR-TB) patients in Indonesia. A
retrospective cohort study was conducted at all MDR-TB treatment healthcare facilities in Indonesia from 2014 to 2015. Using total sampling technique, 961
patients were examined and sampled. Of these patients, 86.03% were decentralized. Patients were classified into types as follows: 35.17% were “relapse”
patients, 5.52% were “new,” 13.94% were classified as “after LTFU” patients, 23.10% were “treatment failure category 1” patients, 20.29% were “treatment
failure category 2” patients, and 1.90% were classified as “other types” patients. Decentralization reduced LTFU risk by up to 46% (HR = 0.54, 95% CI 0.35–
0.84). LFTU in “after LTFU,” “treatment failure category 2,” and “other types” patients was higher by 50%, 53%, 74%, respectively compared to LFTU occur-
rence in “relapse” (baseline) patients. Among “treatment failure category 2 patients, female patients were 2.13 times more likely to have an occurrence of
LFTU, while male patients were 0.55 times as likely to have an occurrence of LFTU, compared to “relapse” type patients of the same sex.
Keywords: Decentralization, loss to follow-up, multidrug-resistant tuberculosis, type of patient
Abstrak
Pasien tuberkulosis (TB) resistan obat memiliki kemungkinan loss to follow-up (LTFU) lebih besar dibandingkan pasien TB sensitif obat dikarenakan durasi
pengobatan yang lebih lama. Penelitian ini bertujuan mengetahui pengaruh desentralisasi dan tipe pasien terhadap LTFU pada pasien multidrug-resistant TB
(MDR-TB) di Indonesia. Sebuah studi kohort retrospektif dilakukan di semua fasilitas kesehatan yang merawat pasien TB-MDR di Indonesia pada tahun
2014–2015. Sampel diambil dalam total sampling dengan total 961 pasien. Sebanyak 86,03% pasien dilakukan desentralisasi. Berdasarkan tipenya, pasien
terdiri dari 35,17% kambuh, 5,52% baru, 13,94% setelah LTFU, 23,10% kegagalan kategori 1, 20,29% kegagalan kategori 2, 1,90% pasien tipe lainnya.
Desentralisasi mengurangi LTFU hingga 46% (HR = 0,54; 95% CI 0,35–0,84). LTFU pada “setelah LTFU”, “kasus gagal pengobatan kategori 2” dan tipe lain-
lain meningkat masing-masing sebesar 50%, 53%, dan 74% dibandingkan dengan pasien kambuh (baseline). Pada kategori kegagalan pengobatan kategori
2, pasien perempuan 2,13 kali dan pasien laki-laki 0,55 kali untuk terjadi LTFU dibandingkan pasien dengan tipe kambuh.
Kata kunci: Desentralisasi, loss to follow-up, multidrug-resistant tuberculosis, tipe pasien
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Introduction
According to the 2018 Global Tuberculosis Report,
tuberculosis (TB) is one of the top 10 causes of death in
the world.1 Among infectious diseases, TB is the third
major cause of death, after lower respiratory tract infec-
tions and diarrhea.2 One of the new challenges in TB
control is the emergence of multidrug-resistant tubercu-
losis (MDR-TB).3 Management of drug-resistant TB is
more complicated and requires more attention than non-
resistant TB management.4 MDR-TB is a type of TB re-
sistance caused by the Mycobacterium tuberculosis bac-
teria. This etiologic agent in humans is resistant to isoni-
azid and rifampicin, two of the most effective medica-
tions for first line anti-TB treatment.5
In 2016, incidence of MDR-TB was 490,000 cases,
84% of which were from 20 high burden countries
(HBCs). These countries had the highest number of
MDR-TB cases in the world. Indonesia is a high burden
country, ranking fourth after India, China, and Russia.
The incidence of MDR-TB in Indonesia was estimated
to be 32,000 cases in 2016.6 In Indonesia, the situation
is further complicated by the high rate of loss to follow-
up (LTFU) during the treatment of MDR-TB patients.
LTFU in MDR-TB patients for cohorts in 2009, 2010,
2011, 2013, and 2014 were 10.5%, 10.7%, 25.1%,
26.9%, 28.7%, and 27.1%, respectively.7 Such high
rates of LTFU overburden the treatment infrastructure
and severely limit the successes of TB control programs.
The re-treatment of MDR-TB patients due to LTFU is
more complex than the treatment of regular TB
patients.4
Due to the longer duration of drug-resistant TB the -
rapy (19–24 months), drug-resistant TB patients have a
greater risk of LTFU than drug-sensitive TB patients (6–
12 months).4,8 In addition, MDR-TB patients who do
not complete treatment have a greater risk of dying from
TB. A study on MDR-TB patients in Peru revealed that
out of 47 (70.1%) LTFU patients successfully traced, 25
(53.2%) had died.9
Decentralization and patient type are factors which
play an important role in the occurrence of LTFU in
MDR-TB patients. Decentralization is the transfer of
treatment and care for MDR-TB patients from MDR-TB
treatment centers or hospitals to community-based
Directly Observed Treatment Short course (DOTS) fa-
cilities.10, 11 Patient type was determined based on pre-
vious TB treatment status (i.e., relapse, new, after LTFU,
treatment failure category 1, treatment failure category
2, and other types). Patients were classified under the
LFTU category if their treatment had been interrupted
for two or more consecutive months.4,12 This study
aimed to explain the influence of decentralization and pa-
tient type on LTFU incidence among MDR-TB patients
in Indonesia in the 2014–2015 cohort.
Method
This was a retrospective cohort study based on record
review of patients enrolled in MDR-TB treatment. This
study was conducted from May to June 2018 at the Sub-
directorate of TB, Directorate of Prevention and
Communicable Disease Control, Directorate General of
Prevention and Disease Control, Ministry of Health of
the Republic of Indonesia. The study population was
MDR-TB patients who started treatment in 2014 and
2015 at all MDR-TB treatment facilities throughout
Indonesia, and whose data had been stored in the e-TB
Manager application. The study sample was derived
from an eligible population that met the inclusion crite-
ria. The inclusion criterion was adult patients with
MDR-TB (age of 15 years), while the exclusion criteria
were drug-resistant TB with resistance patterns other
than MDR (RR, Monoresistant, Polyresistant,
Extensively Drug-resistant/XDR, Pre-XDR, and un-
known pattern of resistance), MDR-TB patients with no
end-of-treatment status, and MDR-TB patients with no
end-of-treatment date.
This study used secondary data based on medical
records of MDR-TB patients stored in the e-TB Manager
application. Using a structured data capture instrument,
data collection and entry into the e-TB Manager had been
routinely performed by recording and reporting officers
at each MDR-TB treatment facility. Sample selection was
carried out using the total sampling technique.
Independent variables included decentralization (no
or yes), patient type (relapse, new, after LTFU, treatment
failure category 1, treatment failure category 2, other
types), sex (female or male), age (45 years or > 45 years),
culture conversion (conversion 4 months, > 4 months,
unknown/no data), location of TB disease (extra pul-
monary or pulmonary), HIV status (negative, positive,
unknown), and side effects (no side effects, unknown, or
any side effects). The main outcome variable was LTFU.
Patients were classified under the LFTU category if their
treatment had been interrupted for two or more consec-
utive months for any reason.12
There were four stages of data processing carried out
for this study.13 The first stage was editing. The com-
pleteness of medical records data and variables drawn
from e-TB Manager was checked. The second stage was
coding. Coding involves changing the data from alpha-
betical form into numerical form. The third was process-
ing. Processing involved entering data from the file for-
mat downloaded in e-TB Manager into the data analysis
program used. The last stage was cleaning. In this stage,
data already entered were rechecked, ensuring the data
were ready to be analyzed.
One of the main independent variables in this study
(namely decentralization) occured lost data more than
10%, so that multiple imputations were carried out on
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this variable. The assumptions of missing data were test-
ed. Statistical tests were conducted to examine missing
data included for completely missing data or data missing
at random. The mean of numerical variables that were
complete with the variables that has the missing data (t-
test). The relation of categorical variable that is filled
with the variable that has the missing data (logistic re-
gression).14
In this study, survival analysis was carried out.
Survival analysis is a statistical procedure to analyze data,
with the outcome variable being the time to event.15 The
event in this study was the occurrence of LTFU. The time
of event was calculated from the beginning of an obser-
vation (starting treatment of MDR-TB) until LTFU oc-
curred.
Patient characteristics were summarized using des -
crip tive statistics. To identify the relationship between
the independent variable and survival time, and to test
proportional hazard (PH) assumption, bivariate analysis
was performed. PH assumption was tested by using
graphical analysis of ln-ln survival estimates and time-de-
pendent variables. The assumption of PH was met if the
curve on the graph of In-ln survival estimates did not in-
tersect and the test of time-dependent variables yielded a
p-value > 0.05. The Cox Extended Regression method
was used to measure the influence of a main independent
variable on outcome, because some covariate variables
did not meet the PH assumption. The next step was to
test the interaction between the main independent vari-
able and the covariate variable. A p-value < 0.05 indicat-
ed the presence of a relationship between both variables.
Moreover, a confounding test was conducted by intro-
ducing all covariate variables gradually one by one start-
ing from the variable with the largest p-value. A variable
was included in the model if it was considered as con-
founder. A variable was considered a confounder if it
caused a 10% change in the main independent (model
without interaction) or on the main independent variable
interact (model with interaction). A confounder may also
cause a <10% change, if the variable was related to the
outcome and main independent variable.
This study has been reviewed and approved by the
Research Ethics Committee of the Faculty of Public
Health, Universitas Indonesia dated on May 14th, 2018
No.452/UN2.F10/ PPM.00.02/2018.
Results
This study showed that of the 961 selected samples,
272 patients (28.40%) were LTFU; making the hazard
rate of 2.88/100 person-months. This means that of any
100 patients with MDR-TB, approximately three patients
were LTFU every month (Figure 1). As presented in
Table 1, all patients were classified according to the fol-
lowing categories: decentralization status, patient status,
and covariate variables. Statistically, the proportion of
decentralized patients categorized as LFTU was lower
than the proportion of LFTU non-decentralized patients
(24.43% vs. 47.06%; p-value < 0.0001). Considering
patient type, the proportion of LTFU patients among “af-
ter LTFU” patients and “other types” patients was higher
than LTFU proportions among “relapse” patients
(40.63% vs. 26.30%, p-value = 0.007 and 50.00% vs.
26.30 %; p-value = 0.019). The occurrence of LTFU
among patients aged > 45 years was higher than the oc-
currence of LTFU among patients aged 45 years
(37.05% vs. 23.63%; p-value < 0.0001). The occurrence
of LTFU in patients with an unknown culture conversion
status was higher than the occurrence of LTFU in pa-
tients who had achieved culture conversion status for
four months (59.02% vs. 16.43%; p-value < 0.0001).
The occurrence of LTFU among patients with an un-
known HIV status was also higher than the occurrence
of LTFU among HIV negative (32.89% vs. 24.31, p-val-
ue = 0.001) patients.
In the multivariable analysis, the location of TB as a
variable was not included in the modeling, because only
1 (0.1%) patient had extra pulmonary TB. Conversion
variables, HIV status and side effects were excluded in
the modeling because they had a very high occurrence of
missing data (unknown group). Based on the interactions
test on the association between decentralization and pa-
tient type with LTFU in MDR-TB patients, it was found
that there was an interaction between patient type and
sex (p-value < 0.05) (Table 2). As for the confounding
test on the relationship between decentralization and pa-
tient type, it was determined that the one confounder
was age group (Table 2).
Decentralized patients had a smaller LTFU hazard
rate compared to non-decentralized patients. After
adjust ing for patient type, sex and age, decentralization
decreased LTFU rate by 46% compared to non-decen-
tralized patients (HR 0.54; 95% CI 0.35–0.84) (Table
Figure 1. Graph of LTFU Cumulative Hazard Estimates of MDF-TB Patients
in Indonesia from 2014 to 2015
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2).
The following patient types: “after LTFU,” “treatment
failure category 2,” and “other types” increased risk of
LTFU by 50% (HR 2.02; 95% CI 1.18–3.45), 53% (HR
2.13; 95% CI 1.24–3.66), and 74% (HR 3.80; 95% CI
1.54–9.36), respectively, compared to “relapse” patients
(baseline), after adjusting for decentralization, sex and
age.
Female patients in the “treatment failure category 2”
group were 2.13 times (95% CI 1.24–3.66) and male pa-
tients in the “treatment failure category 2” were 0.55
times (95% CI 0.15–1,98) as likely to have an incidence
of LTFU than patients of the same sex in the “relapse”
patient type group (Table 2).
Discussion
The percentage of patients with LTFU in this study
was similar to the conclusion from a report by
Subdirectorate of TB which stated that LTFU in MDR-
TB patients in Indonesia for 2014 was 27.1%. Any vari-
ation in results may be attributed to differences in inclu-
sion and exclusion criteria during sampling, such that
not all MDR-TB patients were included in the study. The
time reference for the study was between 2015 and
2016. The proportion of LTFU cases among MDR-TB
patients in Indonesia was above the WHO target of
5%.16
The proportion of LTFU patients found in this study
is similar to that LFTU proportions in a study conducted
in Georgia among in MDR-TB patients, which estimated
LFTU occurrence at 29.0%.17 Another study in India
found a lower occurrence of LTFU, at 19.2%.18 The dif-
ferences in these findings and figures are probably due to
different patient characteristics. In this study, 94.5% of
patients had a previous record of TB treatment, and
therefore, had a greater risk of LTFU. However, only
45.8% of subjects in the Indian study had a previous
record of TB treatment.18
It has been shown that decentralization decreased the
risk of LTFU by 46% (HRadjusted 0.54; 95% CI 0.35–
0.84). The results of this present study are in line with
studies conducted in the Philippines which showed that
transfer of MDR-TB patients to a Directly Observed
Treatment Short Course (DOTS) provider close to the
Table 1. Characteristics of MDR-TB Patients in Indonesia in 2014–2015 Cohort
                                                                                                                                                              Cox Regression
Variable                                                  Category                  Patients (n)     LTFU, n (%)
                                                                                                                                                     HR             95% CI            p-Value
Decentralization                                      No                                   57              24 (47.06)             Ref                          
                                                                Yes                                351              85 (24.43)            0.47          0.31-0.71            0.0001        
Patient type                                              Relapse                          338              86 (26.30)             Ref
                                                                New                                53              19 (36.54)            1.54          0.94-2.53              0.089
                                                                After LTFU                   134              52 (40.63)            1.61          1.14-2.27              0.007        
                                                                Failed category 1           222              54 (25.00)            0.91          0.64-1.27              0.572
                                                                Failed category 2           195              45 (23.44)            0.86          0.60-1.24              0.420
                                                                Others                            19                9 (50.00)            2.28          1.15-4.53              0.019        
Sex                                                           Female                          405            114 (29.16)             Ref
                                                                Male                             556            151 (27.86)            0.94          0.74-1.20              0.643        
Age                                                          < 45 years                      618            142 (23.63)             Ref
                                                                > 45 years                      343            123 (37.05)            1.88          1.47-2.39            0.0001        
 
Conversion                                               < 4 months                    633            104 (16.43)             Ref
                                                                > 4 months                      35                4 (11.76)            0.69          0.25-1.86              0.458
                                                                Unknown                      293            157 (59.02)            8.93        6.89-11.56            0.0001        
Location of TB**                                      Extra pulmonary               1                             0             Ref
                                                                Pulmonary                    960            265 (28.43)                 -                         -                      -        
Baseline AFB smear status                       Negative                        213              62 (29.67)             Ref
                                                                Positive                         748            203 (28.04)            0.95          0.72-1.27              0.735        
Amount of drug-resistant TB strains        2                                    380            112 (30.19)             Ref
                                                                3                                    320              84 (27.18)            0.89          0.67-1.19              0.446
                                                                4                                    261              69 (27.27)            0.95          0.70-1.28              0.736        
HIV status                                               Negative                        477            115 (24.31)             Ref
                                                                Positive                             9                1 (14.29)            0.63          0.09-4.53               0649
                                                                Unknown                      475            149 (32.89)            1.52          1.19-1.94              0.001        
                                                                
Side effects                                              Unknown                      893            246 (28.44)             Ref
                                                                Yes                                  68              19 (27.94)            0.92          0.58-1.47              0.730
                                                                     
Notes: 
*significant, p-value < 0.05, **cannot be analysed, MDR-TB = Multidrug-Resistant Tuberculosis, LTFU = Loss to Follow-up, AFB = Acid-
Fast Bacilli, HIV = Human Immunodeficiency Virus, HR = Hazard Ratio, CI = Confidence Interval, Ref = Reference                                 
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Table 2. Effect of Decentralization and Patient Type on LTFU MDR-TB Patients in Indonesia from 2014 to 2015
Variable                       Categoriy                                        LTFU, n (% Basis)   HRcrude (95% CI)        p-Value          HRadj (95% CI)         p-Value 
                                                                                                                                                                                                                                  
Decentralization          No                                                           24 (47.06)                                   1                                                         1                    
                                   Yes                                                          85 (24.43)          0.47 (0.31–0.71)           0.0001          0.54 (0.35–0.84)           0.006
Patient type                  Relapse                                                   86 (26.30)                                   1                                                         1                    
                                   New                                                        19 (36.54)          1.54 (0.94–2.53)             0.089          1.33 (0.55–3.24)           0.527
                                  After LTFU                                             52 (40.63)          1.61 (1.14–2.27)            0.007*          2.02 (1.18–3.45)           0.010
                                    Treatment failure category 1                   54 (25.00)          0.91 (0.64–1.27)             0.572          0.91 (0.52–1.60)           0.755
                                  Treatment failure category 2                   45 (23.44)          0.86 (0.60–1.24)             0.420          2.13 (1.24–3.66)           0.006
                                  Other types                                               9 (50.00)          2.28 (1.15–4.53)             0.019          3.80 (1.54–9.36)           0.004
Interaction                   New#male                                                                                                                                     1.24 (0.42–3.62)           0.694
                                  After LTFU#male                                                                                                                          0.63 (0.31–1.27)           0.199
                                    Treatment failure category1#male                                                                                                 0.92 (0.45–1.86)           0.818
                                  Treatment failure category 2 #male                                                                                               0.26 (0.12–0.54)         0.0001
                                  Other types#male                                                                                                                          0.26 (0.06–1.17)             0.08
Sex                               Female                                                  114 (29.16)                                   1                                                         1                    
                                    Male                                                     151 (27.86)          0.94 (0.74–1.20)             0.643          1.35 (0.86–2.11)           0.185
Age                              ≤45 years                                             142 (23.63)                                   1                                                         1                    
                                  >45 years                                              123 (37.05)          1.88 (1.47–2.39)           0.0001          2.69 (1.81–4.02)         0.0001
Interaction                   Tvc age                                                                                                                                         0.95 (0.92–0.99)           0.026
Notes: 
MDR-TB = Multidrug-Resistant Tuberculosis, LTFU = Loss to Follow-up, HR = Hazard Ratio, CI = Confidence Interval, Tvc = Time-Varying Covariates
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patient's residence could reduce risk of LTFU by 70%
(HRadjusted 0.3, 95% CI: 0.2–0.7). Decentralization
was implemented after health workers in DOTS health-
care facilities had been trained to manage and monitor
treatment using second-line drugs.11
Another study in Russia showed that adherence to
treatment among MDR patients increased from 56% to
88% when they were treated by a DOTS provider in the
community. In this program, the time and place of daily
medical supervision was chosen by the patient. Nurses
were responsible for only five to seven patients. This was
aimed at creating a sense of community with patients,
close relatives, and colleagues.19 These results were con-
firmed in a systematic review that showed that the in-
volvement of public health officers as DOTS providers
via referrals played a role in decreasing LTFU rates
among MDR-TB patients.20
MDR-TB patients without severe drug side effects or
uncontrolled comorbidities may be referred to and con-
tinue treatment at the closest DOTS provider designated
and prepared as an MDR-TB satellite facility by the local
District Health Office.4 The decentralization or handover
process aims to carry treatment access closer to the pa-
tient's home; hence, reducing the likelihood of a patient
being lost to follow-up.10 LTFU may be due to the high
transportation costs to the hospital. Decentralization can
be more cost-effective, as hospital service costs are usu-
ally higher than service costs at primary healthcare facil-
ities.21
Currently, acceptance of decentralized treatment is
still low due to several factors, including inadequate
knowledge and experience with MDR-TB treatment (side
effects) among local health staff, limited hours of public
health care, lack of patient confidence in local health
staff, and inadequate monitoring of remote primary
health care.22
Patient type influences LTFU incidence. Patient types
such as “after LTFU,” “treatment failure category 2,” and
“other types” exhibited an increased risk of LTFU com-
pared to “relapse” (baseline) patients. Having a previous
LTFU record increased the risk of LTFU by 50%
(HRadjusted 2.02; 95% CI 1.18–3.45). In other words,
LTFU patients were 2.02 times more likely to have an-
other LTFU episode than patients who returned for treat-
ment after successful on previous treatment. The risk of
a LFTU occurrence was 53% higher (HRadjusted 2.13;
95% CI 1.24–3.66) in “treatment failure category 2” pa-
tients compared to patients who returned for treatment
after previous successful treatment. In other words,
“treatment category 2” were 2.13 times more likely to
have a LTFU occurrence than patients who returned for
treatment after previous successful treatment. The risk
of a LFTU occurrence was 74% higher (HRadjusted
3.80, 95% CI 1.54–9.36) in “other types” patients,
meaning patients with no information about previous
records of TB treatment were 3.80 more likely to have a
LTFU occurrence than patients who returned for treat-
ment after previous successful treatment. These results
are in line with a Sri Lankan study which showed that
patient type influenced LTFU risk. This present study
demonstrated that “after LTFU” patients were 2.44 times
(95% CI: 1.03–5.78) more likely to have an occurrence
of LTFU compared to TB patients returning after suc-
cessful treatment. Therefore, when restarting treatment
in previous LTFU patients, it is important to continuous-
ly emphasize adherence to treatment. In these patients,
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prompt follow-up with additional support from local
healthcare facilities may be useful in decreasing LTFU
occurrence.23
A study in Bangalore City, India, showed that the “af-
ter LTFU” patients were 2.5 times (95% CI: 1.3–4.9)
more likely to have an occurrence of LTFU compared
with TB patients who returned after previous successful
treatment.24 The higher LTFU risk among patients un-
dergoing re-treatment could be attributed a high percent-
age of “after LFTU” patients (78%) who had interrupted
previous treatment. Close supervision, motivation and
ensuring that DOT facilities are accessible to patients at
high risk of LFTU should be prioritized at the initiation
of treatment. This may improve the success of treatment,
given that majority (64%) of patients are undergoing re-
treatment.
The results of a study conducted in Nairobi, Kenya
showed that TB patients who returned for treatment after
LTFU were 2.33 (95% CI: 1.16–6.48) more likely to
have an occurrence of LFTU compared to untreated
(new) TB patients and patients who had returned for
treatment after successful treatment.25 Another study
published similar results, showing that “after LFTU” pa-
tients returning for treatment were 6.4 times (95% CI:
2.9–14.0) more likely to have an occurrence of LTFU
among retreatment patients (relapse, failed, and other
types) during subsequent treatment.26 It is important to
prevent initial LFTU occurrence among new patients.
Furthermore, due to greater risk of LFTU, “after LTFU,”
“treatment failure category 2,” and “other types” patients
must be quickly identified and monitored.
Our results showed no association between sex and
LTFU, and is supported by results from a different
study.11 However, other studies have shown an associ-
ation between sex and LFTU occurrence, suggesting
that males had a greater odds of LTFU during MDR-TB
treatment (1.43 times (95% CI 1.15–1.78)) than fe-
males.24
This study had several limitations. The retrospective
cohort study design meant that quality control of previ-
ously recorded measurements was not possible. Data
were missing for several variables due to incomplete
medical records, possibly affecting the ability to detect
relationships between the outcomes and certain vari-
ables, including culture conversion status, HIV status,
and adverse events. Furthermore, unavailability and in-
completeness of data limited the analysis of other poten-
tial confounding variables. Some potential confounding
variables that were not considered in this study included
conversion status, HIV status, adverse events, employ-
ment status, incarceration status, home ownership, drug
use, tobacco use, alcohol use, and treatment disturbance
rates. Therefore, the presence of several residual con-
founding effects in this study cannot be ruled out.
Conclusion
In conclusion, decentralization and patient type are
influential risk factors for LFTU occurrence.
Decentralization reduces the risk of developing LTFU.
Certain patient types (“after LTFU,” “failed treatment
category 2,” and “other types”) have a higher risk of LT-
FU occurrence. Hence, supplementary strategies may be
necessary to prevent occurrence of LTFU, so that the
continuity of MDR-TB treatment can be improved.
Recommendation
Health workers should prioritize communication.
MDR-TB patients should be informed and educated
about treatment, side effects and duration of proper
treatment. Furthermore, the benefits of decentralization
should be demonstrated to MDR-TB patients (especially
those without serious adverse events or uncontrolled co-
morbidities) and their families at the time of visits.
The risk of LTFU is higher in “after LTFU,” “treat-
ment failure category 2,” and “other types” patients com-
pared to “relapse” patients. Therefore, patient type
screening should be conducted at initiation of treatment
to determine a patient’s risk of LTFU. For high LFTU
risk patient types, it is necessary to communicate, inform
and educate the patients on a routine basis on the bene-
fits of adherence to treatment regimen and duration.
Acknowledgment
The researcher would like to thank the Indonesia
Endowment Fund for Education (LPDP RI) that has
funded this study.
References
1. World Health Organization. Global tuberculosis report 2018. Geneva,
Switzerland: World Health Organization; 2018.
2. World Health Organization. WHO _ The top 10 causes of death
[Internet]. Geneva, Switzerland: World Health Organization; 2017 [cit-
ed 2017 Dec 11]. Available from: http://www.who.int/mediacentre/
factsheets/fs310/en/
3. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan
Kementerian Kesehatan Republik Indonesia. Rencana aksi nasional pro-
grammatic management of drug resistance tuberculosis pengendalian
tuberkulosis Indonesia: 2011-2014. Jakarta: Direktorat Jenderal
Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian
Kesehatan Republik Indonesia; 2011.
4. Direktorat Jenderal Pengendalian Penyakit Dan Penyehatan Lingkungan
Kementerian Kesehatan Republik Indonesia. Petunjuk teknis manaje-
men terpadu pengendalian tuberkulosisi resisten obat. Jakarta:
Direktorat Jenderal Pengendalian Penyakit Dan Penyehatan Lingkungan
Kementerian Kesehatan Republik Indonesia; 2013.
5. World Health Organization. Multidrug-resistant tuberculosis (MDR-
TB) 2014 update. Geneva: World Health Organization Press; 2014.
6. World Health Organization. Global tuberculosis report 2017. Geneva,
Switzerland: World Health Organization; 2017.
110
Kesmas: National Public Health Journal, 2019; 13 (3): 105-111
7. Nurjannah. Update kegiatan program TB [Internet]. 2017 [cited 2017
April 22]. Available from: http://www.tbindonesia.or.id/2017/04/
18/materi-monev-2017-makasar-10-13-april-2017/
8. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkunga
Kementerian Kesehatan Republik Indonesia. Pedoman nasional pen-
gendalian tuberkulosis. Jakarta: Direktorat Jenderal Pengendalian
Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan Republik
Indonesia; 2014.
9. Franke MF, Appleton SC, Bayona J, Arteaga F, Llaro K, Shin SS, et al.
Risk factors and mortality associated with default from multidrug-resis-
tant tuberculosis treatment. Clinical Infectious Disease.
2009;46(12):1844–51.
10. Kementrian Kesehatan Republik Indonesia. Buku saku pengendalian
TB-RO untuk petugas fasyankes. Jakarta: Kementrian Kesehatan
Republik Indonesia; 2014. 1–79 p.
11. Gler MT, Podewils LJ, Munez N, Galipot M, Quelapio MID, Tupasi TE.
Impact of patient and program factors on default during treatment of
multidrug-resistant tuberculosis. International Journal of Tuberculosis
and Lung Disease [Internet]. 2012;16(7):955–60. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/22584124
12. World Health Organisation. Definitions and reporting framework for
tuberculosis–2013 revision [Internet]. Geneva: World Health
Organisation; 2014. 9–11 p. Available from: http://apps.who.int/iris/
bitstream/10665/79199/1/9789241505345_eng.pdf?ua=1%0Ahttp://
apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
13. Hastono SP. Analisis data pada bidang kesehataan. 1st ed. Jakarta:
Rajawali Pers; 2016.
14. Harlan J. Data kosong dan imputasi ganda. Depok: Gunadarma; 2016.
15. Kleinbaum DG, Klein M. Survival analysis: a self learning text. 3rd ed.
Gail M, Krickerberg K, Samet JM, editors. New York: Springer; 2014.
1–700 p.
16. World Health Organization. Roadmap to prevent and combat drug-re-
sistant tuberculosis: the consolidated action plan to prevent and combat
multidrug- and extensively drug-resistant tuberculosis in the WHO
European Region 2011–15. resolution EUR/RC61/R7. Copenhagen,
Denmark: World Health Organization; 2011.
17. Kuchukhidze G, Kumar AM V, Colombani P de, Khogali M, Nanava U,
Blumberg HM, et al. Risk factors associated with loss to follow-up
among multidrug-resistant tuberculosis patients in Georgia. Public
Health Action. 2014; 4 (Suppl 2): 541-6.
18. Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK. Loss-to-follow-up on
multidrug resistant tuberculosis treatment in Gujarat, India : the when
and who of it. PLOS ONE. 2015; 10(7): e0132543.
19. Keshavjee S, Gelmanova IY, Pasechnikov AD, Mishustin SP, Andreev
YG, Yedilbayev A, et al. Treating multidrug-resistant tuberculosis in
Tomsk, Russia: developing programs that address the linkage between
poverty and disease. Annals of The New York Academy of Sciences.
2008;1136:1–11.
20. Toczek A, Cox H, Cros P du, Cooke G, Ford N. Strategies for reducing
treatment default in drug-resistant tuberculosis: systematic review and
meta- analysis. International Journal of Tuberculosis and Lung Disease
[Internet]. 2012; 17 (3): 299–307. Available from: https://www.
ncbi.nlm.nih.gov/pubmed/23211716
21. Soepandi PZ. Output of treatment and cost variations of TB - MDR /
XDR with PMDT strategy in RSUP Persahabatan. Jurnal Administrasi
Kebijakan Kesehatan. 2014;1(1):19–25.
22. Tiemersma EW, Hafidz F. Costs faced by (multidrug resistant) tubercu-
losis patients during diagnosis and treatment report from a pilot study
in Indonesia [Internet]. 2014. Available from: https://www.chal-
lengetb.org/publications/tools/costing/Cost_Faced_by_MDR-
TB_Patients_Indonesia.pdf
23. Pinidiyapathirage J, Senaratne W, Wickremasinghe R. Prevalence and
predictors of default with tuberculosis treatment in Sri Lanka. Southeast
asian Journal of Tropical Medicine and Public Health.
2008;39(6):1076–82.
24. Vijay S, Balasangameswara VH, Jagannatha PS, Saroja VN, Kumar P.
Defaults among tuberculosis patients treated under DOTS in Bangalore
City: a search for solution. Indian Journal Tuberculosis. 2003;50:185–
95.
25. Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya
F. Factors associated with default from treatment among tuberculosis
patients in Nairobi Province, Kenya : A case control study. BMC Public
Health [Internet]. 2011;11(1):696. Available from: http://www.bio-
medcentral.com/1471-2458/11/696
26. Finlay A, Lancaster J, Holtz TH, Weyer K, Miranda A, Walt M Van Der.
Patient- and provider-level risk factors associated with default from tu-
berculosis treatment, South Africa, 2002 : a case control study. BMC
Public Health [Internet]. 2012;12(1):56. Available from:
http://www.biomedcentral.com/1471-2458/12/56
111
Noerfitri et al, Influence of Decentralization and Type of Patient on Loss to Follow-up among Multidrug-Resistant Tuberculosis Patients
